Dear sir,
I wich to ask if some one have any informations about the risks of monoclonal anti body drug production ? and the points wich interest regulatory authorities , related to the AMM, Post AMM.
What about biosimilaries of this kind of drugs ?
Thanks
yours faithfully
-------------------------------------------
Yacine ABOURA
Student
UCL
Wezembeek-Opeem
Belgium
-------------------------------------------